Tenenbaum, Alexander

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphisms

Cited by 246

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry

Klempfner, R., Erez, A., Sagit, B.-Z., Goldenberg, I., Fisman, E., Kopel, E., Shlomo, N., Israel, A., & Tenenbaum, A. (2016) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 180

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

Fisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 124

Functional class in patients with heart failure is associated with the development of diabetes

Tenenbaum, A., Motro, M., Fisman, E. Z., Leor, J., Freimark, D., Boyko, V., Mandelzweig, L., Adler, Y., Sherer, Y., & Behar, S. (2003) · The American Journal of Medicine

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 99